GlassScriptPhysician profile
Tamar C Carmel
NPI 1477782365
$7,987.42
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $353 · 2021: $3,547 · 2022: $3,841.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,947.62 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $2,051.70 | 2019-2022 | |
| Abbvie INC. | $243.99 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $165.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $105.95 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $103.61 | 2020-2021 | |
| Allergan, INC. | $64.60 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.33 | 2021 | |
| Theratechnologies INC. | $35.89 | 2019 | |
| Indivior INC. | $34.64 | 2019-2021 | |
| Hologic Sales and Service, LLC | $29.66 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $29.14 | 2020-2021 | |
| Seqirus USA INC | $24.20 | 2019 | |
| Alkermes, INC. | $20.35 | 2020 | |
| Lundbeck LLC | $20.13 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.92 | 2019 | |
| Virtus Pharmaceuticals LLC | $18.07 | 2022 | |
| Vyera Pharmaceuticals, LLC | $14.16 | 2019 | |
| Mdd US Operations, LLC | $12.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamar Carmel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.